Synaptogenix (SNPX) 8-K Financial Statements and Exhibits

Exhibit 99.1

SYNAPTOGENIX, INC.

BALANCE SHEETS

(Unaudited) 

	As Filed			Offering		Pro forma as of
	December 31,			Entries		December 31,
	2020			January 2021		2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	5,795,055		$	12,589,667	$	18,384,722
Grant receivable		127,445			-		127,445
Prepaid expenses and other current assets		806,289			-		806,289
TOTAL CURRENT ASSETS		6,728,789			12,589,667		19,318,456
Fixed assets, net of accumulated depreciation		22,212			-		22,212
TOTAL ASSETS	$	6,751,001		$	12,589,667	$	19,340,668
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	1,260,335		$	-	$	1,260,335
Accrued expenses		352,154			-		352,154
TOTAL CURRENT LIABILITIES		1,612,489			-		1,612,489
Commitments and contingencies
SHAREHOLDERS' EQUITY
Preferred stock - 1,000,000 shares authorized as of December 31, 2020, $0.0001 par value;
0 shares issued and outstanding as of December 31, 2020
Common stock - 150,000,000 shares authorized as of December 31, 2020, $0.0001 par value;		-			-		-
5,030,316 shares issued and outstanding as of December 31, 2020
14,032,516 pro forma shares issued and outstanding as of December 31, 2020.		503			900		1,403
Additional paid-in capital		6,668,482			12,588,767		19,257,249
Accumulated deficit		(1,530,473	)		-		(1,530,473	)
TOTAL SHAREHOLDERS' EQUITY		5,138,512			12,589,667		17,728,179
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	6,751,001		$	12,589,667	$	19,340,668